Search results
Showing 1 to 9 of 9 results for phosphate binder
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
NG203/16 Question Phosphate binders: Which binders are the most clinically and cost effective in controlling...
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
their family members and carers views and beliefs about taking oral phosphate binders? Any explanatory notes(if applicable)...
Recommendation ID NG203/17 Question Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what...
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
CG157/1 | Phosphate binders in adults with chronic kidney disease (CKD) stage 4 or 5:- Which binders are most...